Citation Impact
Citing Papers
Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae
2006
Dissociation between Inhibition and Killing by Levofloxacin in Human Granulocytic Anaplasmosis
2006
Multiple Drug-Resistant Mycobacterium tuberculosis: Evidence for Changing Fitness Following Passage Through Human Hosts
2002
Review on plant antimicrobials: a mechanistic viewpoint
2019 Standout
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
2019 Standout
Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds
1998
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
2000 Standout
Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa
2004
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
2007 Standout
Antimicrobial Resistance with Streptococcus pneumoniae in the United States, 1997–98
1999
Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy
2003
Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
2003 Standout
Quinolones Inhibit DNA Religation Mediated by Staphylococcus aureus Topoisomerase IV
1999
Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
2010
Pseudomonas Aeruginosa: Resistance to the Max
2011 Standout
Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
1999
DNA gyrase as a drug target
1997
Optical control of antibacterial activity
2013 StandoutNobel
Antibiotics bioremediation: Perspectives on its ecotoxicity and resistance
2019 Standout
Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2
2011
Mechanisms of antibiotic resistance and tolerance in
2000 StandoutNobel
Better Control of Antibiotic Resistance
2001
What is a resistance gene? Ranking risk in resistomes
2014 Standout
Gemifloxacin: a new fluoroquinolone
2004
Skeletal infections: microbial pathogenesis, immunity and clinical management
2022 Standout
Antibacterial resistance worldwide: causes, challenges and responses
2004 Standout
Antibiotic resistance and its cost: is it possible to reverse resistance?
2010 Standout
Drug Interactions with Bacillus anthracis Topoisomerase IV: Biochemical Basis for Quinolone Action and Resistance
2011
The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing
2008 Standout
Fluoroquinolone‐ResistantStreptococcus pneumoniaeAssociated with Levofloxacin Therapy
2001
Clinical Features and Prognostic Factors in Adults with Bacterial Meningitis
2004 Standout
Resistance to Antibiotics: Are We in the Post-Antibiotic Era?
2005 Standout
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance
2013
Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions
2001
Increasing Prevalence of Multidrug-ResistantStreptococcus pneumoniaein the United States
2000
Fluoroquinolones: Action and Resistance
2003
Topoisomerase IV Catalysis and the Mechanism of Quinolone Action
1998
Oxazolidinones: activity, mode of action, and mechanism of resistance
2004 Standout
Call of the wild: antibiotic resistance genes in natural environments
2010 Standout
Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions
2015 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q
2006 StandoutNobel
Antibacterial mechanism of soybean isoflavone on Staphylococcus aureus
2010
Antimicrobial strategies centered around reactive oxygen species – bactericidal antibiotics, photodynamic therapy, and beyond
2013 Standout
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment
2006 Standout
Quinolones: Action and Resistance Updated
2009
Mechanisms of Resistance to Quinolones
2005
Recent advances in understanding the antibacterial properties of flavonoids
2011 Standout
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
2007 Standout
Mechanism of Quinolone Action and Resistance
2014 Standout
Invasive Methicillin-Resistant <EMPH TYPE="ITAL">Staphylococcus aureus</EMPH> Infections in the United States
2007 Standout
How antibiotics kill bacteria: from targets to networks
2010 Standout
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Guidelines for the Management of Adults with Community-acquired Pneumonia
2001 Standout
Treatment of drug-resistant pneumococcal pneumonia
2002
Mechanisms of Antibiotic Resistance
2016 Standout
Survival strategies of infectious biofilms
2004 Standout
Antibiotics and Bacterial Resistance in the 21st Century
2014 Standout
TROSY in triple-resonance experiments: New perspectives for sequential NMR assignment of large proteins
1998 StandoutNobel
The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms
2018
Probing the Differential Interactions of Quinazolinedione PD 0305970 and Quinolones with Gyrase and Topoisomerase IV
2009
Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae
1998
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
2014 Standout
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA , parC , and parE Loci
1999
Sampling the Antibiotic Resistome
2006 StandoutScience
PBP4: A New Perspective on Staphylococcus aureus β-Lactam Resistance
2018
Alteration in the GyrA Subunit of DNA Gyrase and the ParC Subunit of DNA Topoisomerase IV in Quinolone-Resistant Clinical Isolates of Staphylococcus epidermidis
1998
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
2006 Standout
Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones
2008
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
1998
Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones
2002
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
2006 Standout
Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones
1997
Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance
2001 Standout
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings
2007 Standout
Horizontal Transfer of parC and gyrA in Fluoroquinolone-Resistant Clinical Isolates of Streptococcus pneumoniae
2000
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
1997
Contribution of Topoisomerase IV Mutation to Quinolone Resistance in Mycoplasma genitalium
2013
Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
2003
Molecular Characterization of Acquired Enrofloxacin Resistance in Mycoplasma synoviae Field Isolates
2013
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones
1997
Molecular Biology and Pathogenicity of Mycoplasmas
1998 Standout
Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae
2003
Amino acid variation in the GyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics
1997
Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins
2001
Emerging Targets in Photopharmacology
2016 StandoutNobel
DNA gyrase, topoisomerase IV, and the 4-quinolones
1997
Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia
2010
Prevalence of gyrA , gyrB , parC , and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season
2000
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae
1997
Works of Jane E. Ambler being referenced
Fluoroquinolone Resistance in Streptococcus pneumoniae : Evidence That gyrA Mutations Arise at a Lower Rate and That Mutation in gyrA or parC Predisposes to Further Mutation
2003
Mutator plasmid in a nalidixic acid-resistant strain of Shigella dysenteriae type 1
1993
Positive R plasmid mutator effect on chromosomal mutation to nalidixic acid resistance in nalidixic acid-exposed cultures of Escherichia coli
1995
Activity of Gemifloxacin against Penicillin- and Ciprofloxacin-Resistant Streptococcus pneumoniae Displaying Topoisomerase- and Efflux-Mediated Resistance Mechanisms
1999
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
1996
Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro
2000
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program
2015
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program
2015